[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-2347":3,"doc-seo-2347":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"table_of_contents":24,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},2347,4398048949847,"Eliana","https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267",8,"Research & Report","Development of Solid Lipid Nanoparticles of Diacerein in a Stable Oral Liquid Dosage Form Using a Central Composite Design","Diacerein (DCN) is used for conditions such as osteoarthritis but suffers from poor chemical stability in aqueous liquid formulations. Solid lipid nanoparticles (SLNs) using cetyl alcohol as the lipid matrix and Tween 80 as surfactant were formulated and optimized via a quality-by-design approach using a central composite design. The optimized SLNs were incorporated into a structured vehicle to create a stable oral liquid (50 mg/5 mL). Accelerated stability testing at 40 °C/75% RH for 6 months showed robustness, while encapsulation reduced diacerein-related diarrhea.","cbCaiii5yQNpBybu","https://ap.wps.com/l/cbCaiii5yQNpBybu","pdf",2625811,11,1,15,"English","en","",1776276081,38,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":23,"slug":31,"title":13,"keywords":24,"description":14,"schema_data":32,"social_meta":67,"head_meta":70,"extra_data":72,"updated_unix":25},105,"development-of-solid-lipid-nanoparticles-of-diacerein-in-a-stable-oral-liquid-dosage-form-using-a-central-composite-design",{"@graph":33,"@context":66},[34,51],{"@type":35,"itemListElement":36},"BreadcrumbList",[37,41,45,48],{"item":38,"name":39,"@type":40,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":42,"name":43,"@type":40,"position":44},"https://docshare.wps.com/document/","Document",2,{"item":46,"name":12,"@type":40,"position":47},"https://docshare.wps.com/document/research-report/",3,{"item":49,"name":13,"@type":40,"position":50},"https://docshare.wps.com/document/development-of-solid-lipid-nanoparticles-of-diacerein-in-a-stable-oral-liquid-dosage-form-using-a-central-composite-design/2347/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":60,"encodingFormat":58,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":38,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-06-01","2026-04-15",true,{"@type":63,"interactionType":64,"userInteractionCount":19},"InteractionCounter",{"@type":65},"ViewAction","https://schema.org",{"og:url":68,"og:type":69,"og:title":13,"og:site_name":56,"og:description":14},"https://docshare.wps.com/document/development-of-solid-lipid-nanoparticles-of-diacerein-in-a-stable-oral-liquid-dosage-form-using-a-central-composite-design/2347","article",{"robots":71,"canonical":68},"index,follow",{"doc_id":7,"site_id":30}]